Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease

Borman, 1996, Résistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug, J. Gen. VIrol., 77, 419, 10.1099/0022-1317-77-3-419 Dearman, 1996, Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens, Immunology, 89, 502, 10.1046/j.1365-2567.1996.d01-778.x Katzenstein, 1992, Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment, JAIDS, 5, 107 Katzenstein, 1996, Longitudinal serum HIV RNA quantification: correlation to a viral phenotype at seroconversion and clinical outcome, AIDS, 10, 167, 10.1097/00002030-199602000-00006 Lafeuillade, 1997, Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes, AIDS, 11, 67, 10.1097/00002030-199701000-00010 Matsiota-Bernard, 1995, Inhibition of in vitro HIV infection by trinitrophenyl-protein conjugates, Res. Virol., 146, 109 Medina, 1995, Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine, J. Virol., 69, 1606, 10.1128/JVI.69.3.1606-1611.1995 Mellors, 1995, Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion, Ann. Intern. Med., 122, 573, 10.7326/0003-4819-122-8-199504150-00003 Mulder, 1994, Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection, J. Clin. Microbiol., 32, 292, 10.1128/JCM.32.2.292-300.1994 Perelson, 1996, HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 1582, 10.1126/science.271.5255.1582 Saag, 1996, HIV viral load markers in clinical practice, Nat. Med., 2, 625, 10.1038/nm0696-625 Stricker, 1993, Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficiency virus infection, Immunol. Letters, 36, 1, 10.1016/0165-2478(93)90060-F Stricker, 1994, Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochloro-benzene (DNCB), J. Am. Acad. Dermatol., 31, 462, 10.1016/S0190-9622(94)70212-8 Stricker, 1995, Improved results of delayed-type hypersensitivity skin testing in HIV-infected patients treated with topical dinitrochlorobenzene, J. Am. Acad. Dermatol., 33, 608, 10.1016/0190-9622(95)91279-7 Stricker, 1995, Quantitation of human immunodeficiency virus type 1 (HIV-1) RNA in plasma: clinical correlates, Res. Virol., 146, 151, 10.1016/0923-2516(96)81084-3 Stricker, 1996, Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor, Clin. Immunol. Immunopathol., 79, 194, 10.1006/clin.1996.0067 Stricker, 1997, Combination antiretroviral therapy and topical immune modulation with dinitrochlorobenzene (DNCB) in HIV disease, J. Allergy Clin. Immunol., 99, S Terashita, 1996, Enhancement of delayed-type hypersensitivity to sheep red blood cells in mice by granulocyte colony-stimulating factor administration at the elicitation phase, J. Immunol., 156, 4638, 10.4049/jimmunol.156.12.4638 Traub, 1995, Use of dinitrochlorobenzene (DNCB) as an immune modulator in HIV-positive patients: a pilot study from Brazil, Blood, 86, 935a Volberding, 1996, HIV quantification: clinical applications, Lancet, 347, 71, 10.1016/S0140-6736(96)90205-6 Zhu, 1995, Quantitative analysis of HIV-1 RNA in plasma preparations, J. Virol. Methods, 52, 287, 10.1016/0166-0934(94)00149-B